{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:54:25Z","timestamp":1792936465086,"version":"4.5.0"},"reference-count":124,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2020MB106"],"award-info":[{"award-number":["ZR2020MB106"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2020MB013"],"award-info":[{"award-number":["ZR2020MB013"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/13543776.2025.2462849","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T09:00:42Z","timestamp":1738746042000},"page":"409-440","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020\u20132024)"],"prefix":"10.1080","volume":"35","author":[{"given":"Qiaohong","family":"Geng","sequence":"first","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Changyi People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Du","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrui","family":"Jin","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Song","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Qu","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changnan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxing","family":"Su","sequence":"additional","affiliation":[{"name":"Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-6499","authenticated-orcid":false,"given":"Peifu","family":"Jiao","sequence":"additional","affiliation":[{"name":"Qilu Normal University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1801640"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666171004120152"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666181112114958"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.1089.65.3"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29020454"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12670"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.015"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri727"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.225"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)80047-8"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741033"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"e_1_3_6_25_1","unstructured":"Mei D He B Lv S et al. Suzhou Guokuang Pharmtech Co Ltd. CTLA-4 small molecule degradation agent and application thereof. WO2022194248A1. 2022."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1663"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323382"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.03.013"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.010"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah3374"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2690"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00054"},{"key":"e_1_3_6_38_1","unstructured":"Liu X Chen X Li Y et al. Longivitron Suzhou Biotechnology Co Ltd. Biphenyl compound pharmaceutical composition method for preparing same and use thereofp. WO2023236924A1. 2023."},{"key":"e_1_3_6_39_1","unstructured":"Gao K Wang L Li Y et al. Lanzhou University. Preparation method and application of five prenylated flavonoids. CN111747920A. 2020."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205085120"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666181112114958"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0412"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.6026\/97320630015139"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105034"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00370"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01422"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113001"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135900"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.136487"},{"key":"e_1_3_6_53_1","unstructured":"Zhimin D Michael G Paulo MT et al. Gilead Sciences Inc. PD-1\/PD-L1 inhibitors. WO2020086556A1. 2020."},{"key":"e_1_3_6_54_1","unstructured":"Evangelos A Aesop C Michael G et al. Gilead Sciences Inc. PD-1\/PD-L1 inhibitors. WO2020014643A1. 2020."},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25417-6"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008547"},{"key":"e_1_3_6_57_1","unstructured":"Li J Wu L Yao W. Incyte Corporation. Pyrido[3 2-d]pyrimidine compounds as immunomodulators. WO2021067217A1. 2021."},{"key":"e_1_3_6_58_1","unstructured":"Soponpong J Ruengsatra T Nalinratana N et al. Chulalongkorn University. 1 4-Diphenyl-1H-indazole and 1-pyridin-2-yl-4-phenyl-1H-indazole derivatives as PD-1\/PD-L1 modulators for the treatment of cancerp. WO2023250335A1. 2023."},{"key":"e_1_3_6_59_1","unstructured":"Soponpong J Ruengsatra T Nalinratana N et al. Chulalongkorn University. 4-Phenyl-indole derivatives and related usesp. WO2022147302A1. 2022."},{"key":"e_1_3_6_60_1","unstructured":"Zhang M Zhang Y Yu H et al. Abbisko Therapeutics Co Ltd. Immunosuppressive agent preparation method therefor and pharmaceutical use thereofp. WO2020011209A1. 2020."},{"key":"e_1_3_6_61_1","unstructured":"Yang F Zhang Y Yu H et al. Abbisko Therapeutics Co Ltd. Biphenyl derivatives for blocking PD-1\/PD-L1 interaction preparation method therefor and use thereofp. WO2021008491A1. 2021."},{"key":"e_1_3_6_62_1","unstructured":"Zhang M Zhao B Yang F et al. Abbisko Therapeutics. Immunosuppressant and preparation method therefor and use thereofp. WO2021254005A1. 2021."},{"key":"e_1_3_6_63_1","unstructured":"Yang F Zhang Y Yu H et al. Abbisko Therapeutics Co Ltd. Holosymmetric biphenyl derivative and preparation method therefor and use thereofp. WO2023169373A1. 2023."},{"key":"e_1_3_6_64_1","unstructured":"Wang Y Zhang Y Fu B et al. Betta Pharmaceuticals Co Ltd. Immunomodulators compositions and methods thereofp. WO2020156323A1. 2020."},{"key":"e_1_3_6_65_1","unstructured":"Wang Y Zhang Y Zhang C et al. Betta Pharmaceuticals Co Ltd. Immunomodulators compositions and methods thereofp. WO2022022600A1. 2022."},{"key":"e_1_3_6_66_1","unstructured":"Zhang Y Deng J Feng Z et al. Shanghai Ennovabio Pharmaceuticals Co Ltd. Preparation and application of class of N-containing heterocyclic compounds having immunoregulatory functionp. WO2020024997A1. 2020."},{"key":"e_1_3_6_67_1","unstructured":"Zhang Y Feng Z Jiang L et al. Shanghai Ennovabio Pharmaceuticals Co Ltd. Preparation and application of class of N-containing heterocyclic compounds with immunomodulatory functionp. WO2021121282A1. 2021."},{"key":"e_1_3_6_68_1","unstructured":"Zhang Y Cheng Z Feng Z et al. Shanghai Ennovabio Pharmaceuticals Co Ltd. Preparation and use of compound having immunomodulatory functionp. WO2022253327A1. 2022."},{"key":"e_1_3_6_69_1","unstructured":"Li P Xu B Wen Q et al. Adlai Nortye Biopharma Co Ltd. PD-L1 antagonist compound. WO2020169058A1. 2020."},{"key":"e_1_3_6_70_1","unstructured":"Yu Z Li P Xu B et al. Adlai Nortye Biopharma Co Ltd. PD-L1 antagonist compound. WO2021129584A1. 2021."},{"key":"e_1_3_6_71_1","unstructured":"Chen J Liang B Wang P et al. Ascletis Bioscience Co Ltd. Compounds as immunomodulators of PD-L1 interactionsp. WO2023019430A1. 2023."},{"key":"e_1_3_6_72_1","unstructured":"Yang B Chen J Lai Y et al. Ascletis Bioscience Co Ltd. Heterocyclic compounds as immunomodulators of PD-L1 interactionsp. WO2023272720A1. 2023."},{"key":"e_1_3_6_73_1","unstructured":"Fan P Lange C Mali VR et al. Chemocentryx Inc. Triaryl compounds for treatment of PD-L1 diseasesp. WO2020232256A1. 2020."},{"key":"e_1_3_6_74_1","unstructured":"Malathong V Fan P Lange C et al. Chemocentryx Inc. Compounds for treatment of PD-L1 diseasesp. WO2020257549A2. 2020."},{"key":"e_1_3_6_75_1","unstructured":"Malathong V Mali VR Mcmurtrie DJ et al. Chemocentryx Inc. Indanes as PD-L1 inhibitors. WO2021007386A1. 2021."},{"key":"e_1_3_6_76_1","unstructured":"Fan P Lange CW Lui RM et al. Chemocentryx Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesp. WO2021076688A1. 2021."},{"key":"e_1_3_6_77_1","unstructured":"Fan P Lange CW Lui RM et al. Chemocentryx Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesp. WO2021076691A1. 2021."},{"key":"e_1_3_6_78_1","unstructured":"Yu J Xin L Shan S et al. Shenzhen Chipscreen Biosciences Co Ltd. Biphenyl compound as immunomodulatory agent and use thereofp. WO2020043154A1. 2020."},{"key":"e_1_3_6_79_1","unstructured":"Wang Z Bai H Li D et al. Shanghai Longwood Biopharmaceuticals Co Ltd. Novel tricyclic aromatic heterocyclic compound preparation method therefor pharmaceutical composition and application thereofp. WO2021047547A1. 2021."},{"key":"e_1_3_6_80_1","unstructured":"Wang Z Bai H Li D et al. Shanghai Longwood Biopharmaceuticals Co Ltd. Aromatic heterocyclic compound having tricyclic structure and preparation method therefor and application thereofp. WO2021047553A1. 2021."},{"key":"e_1_3_6_81_1","unstructured":"Wang Z Qian A Li D. Shanghai Longwood Biopharmaceuticals Co Ltd. Preparation of aromatic heterocyclic derivative as immunomodulator and application thereof. 2021p. WO2021047555A1."},{"key":"e_1_3_6_82_1","unstructured":"Wang Z Qian A Li D et al. Shanghai Longwood Biopharmaceuticals Co Ltd. Nitrogen-containing heterocyclic compound and preparation method therefor pharmaceutical composition comprising same and use thereofp. WO2021047556A1. 2021."},{"key":"e_1_3_6_83_1","unstructured":"Zhou X Liu X Hu M. Hangzhou Hertz Pharmaceutical Co Ltd. Immunomodulatory Compd composition and application thereof. WO2021093817A1. 2021."},{"key":"e_1_3_6_84_1","unstructured":"Wu Y Zhou X Liu X et al. Hangzhou Healzen Therapeutics Co Ltd. Polysubstituted benzene PD-L1 inhibitor composition and use thereofp. WO2023006019A1. 2023."},{"key":"e_1_3_6_85_1","unstructured":"Wu T Raboisson P-M Stoycheva AD et al. Aligos Therapeutics Inc. Methods and compositions for targeting PD-L1. WO2021236771A1. 2021."},{"key":"e_1_3_6_86_1","unstructured":"Wu T Raboisson P-M Gonzalvez F et al. Aligos Therapeutics Inc. Methods and compositions for targeting PD-L1. WO2022040002A1. 2022."},{"key":"e_1_3_6_87_1","unstructured":"Wu T Raboisson P-M Gonzalvez F et al. Aligos Therapeutics Inc. Methods and compositions for targeting PD-L1. WO2022266236A1. 2022."},{"key":"e_1_3_6_88_1","unstructured":"Wu T Raboisson P-M Gonzalvez F. Aligos Therapeutics Inc. Methods and compositions for targeting PD-L1. 2023p. WO2023114365A1."},{"key":"e_1_3_6_89_1","unstructured":"Chun K Kim H Choi YI et al. Kainos Medicine Inc. Pyridine derivatives as immunomodulators. WO2021246781A1. 2021."},{"key":"e_1_3_6_90_1","unstructured":"Jiang S Hao H Wang T et al. China Pharmaceutical University. Phenyl-substituted five-membered heterocyclic compound preparation method therefor use thereof and pharmaceutical composition comprising samep. WO2021031788A1. 2021."},{"key":"e_1_3_6_91_1","unstructured":"Sun H Liu L Wang S et al. China Pharmaceutical University. Biphenyl compounds preparation method therefor and medical use thereofp. WO2021043116A1. 2021."},{"key":"e_1_3_6_92_1","unstructured":"Lai Y Ouyang Y Zhao L et al. China Pharmaceutical University. Nitrophenyl ether compound preparation method therefor pharmaceutical composition thereof and use thereofp. WO2021148043A1. 2021."},{"key":"e_1_3_6_93_1","unstructured":"Feng Z Chen H. Institute of Materia Medica Chinese Academy of Medical Scicences. Benzisothiazole compound and preparation method therefor and pharmaceutical composition and use thereof. 2022p. WO2022105782A1."},{"key":"e_1_3_6_94_1","unstructured":"Feng Z Yang Y. Institute of Materia Medica Chinese Academy of Medical Scicences. Indoline derivative preparation method therefor pharmaceutical composition and use. 2023p. WO2023050104A1."},{"key":"e_1_3_6_95_1","unstructured":"Rajagopal S Sadhu N Sivanandhan D et al. Jubilant Prodel Llc. Compounds as PD1\/PD-L1 inhibitors and methods thereofp. WO2022224278A1. 2022."},{"key":"e_1_3_6_96_1","unstructured":"Xu Y Du H Zhu Q et al. Xian Xintong Pharmaceutical Res Co Ltd. Novel bicyclic PD-L1 inhibitors preparation methods therefor and medicinal uses thereofp. WO2024109462A1. 2024."},{"key":"e_1_3_6_97_1","unstructured":"Mc Gowan DC Jacoby E. Janssen Sciences Ireland Unlimited Company. Heterocyclic immunomodulators as PD-L1 checkpoint inhibitor. WO2020245372A1. 2020."},{"key":"e_1_3_6_98_1","unstructured":"Trainor GL Molinoff P Nefzi A et al. Relive Therapeutics Inc. Compounds comprising a three ring core as PD-1\/PD-L1 blockersp. WO2021248231A1. 2021."},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002775200"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002788200"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01347-4"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6841"},{"key":"e_1_3_6_103_1","unstructured":"Chunhong M Xinyong L Rong X et al. Shandong University. Targeting Siglec-9 small-molecule inhibitor for promoting anti-tumor and anti-virus functions of immune cells and application of targeting Siglec-9 small-molecule inhibitor. CN116253706. 2022."},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.028"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/415536a"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.01.016"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.03.004"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107933"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1865814"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21099-2"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S170385"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01336"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00960"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115583"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1674"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010"},{"key":"e_1_3_6_119_1","unstructured":"Feng X Zhenmin Z Zhixuan Z et al. Shenzhen Small Molecular New Drug Innovation Center Co Ltd. TIGIT inhibitor and application thereof. CN115068469A. 2022."},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100660"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03116-0"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1293215"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811067116"},{"key":"e_1_3_6_125_1","unstructured":"Jiang S Xiao Y Wang T et al. Yaokang Zhongtuo Jiangsu Pharmaceutical Tech Co Ltd. Heterocyclic compound and preparation method therefor and use thereof. WO2022095569A1. 2022."},{"key":"e_1_3_6_126_1","unstructured":"Gabr M Gambhir S. The Board of Trustees of the Leland Stanford Junior University. VISTA inhibitors. WO2022055940A1. 2022."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2462849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T06:37:57Z","timestamp":1743489477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2462849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/13543776.2025.2462849"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2462849","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}